Clinical Trials Logo

Clinical Trial Summary

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are "double-blind," which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world. Participants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. Participants will have the option of participating in a 2-year, open-label, Extension Period receiving IV ABBV-916. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05291234
Study type Interventional
Source AbbVie
Contact ABBVIE CALL CENTER
Phone 844-663-3742
Email abbvieclinicaltrials@abbvie.com
Status Recruiting
Phase Phase 2
Start date August 15, 2022
Completion date March 26, 2031

See also
  Status Clinical Trial Phase
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT02681172 - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Phase 4
Completed NCT02593318 - Trial of Oxaloacetate in Alzheimer's Disease (TOAD) Phase 1
Completed NCT02264899 - MEMENTO-VAScular COmponents of Dementia N/A
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Not yet recruiting NCT05592678 - δ in Dementia Clinical Trials Phase 2/Phase 3
Recruiting NCT04570761 - Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study N/A
Not yet recruiting NCT05558709 - Social-cognitive Functioning: Validation of a New Neuropsychological Test N/A
Recruiting NCT05059158 - Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Recruiting NCT02832921 - Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk N/A
Completed NCT02370524 - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease Phase 1
Completed NCT01780519 - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms Phase 1
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Completed NCT03802162 - A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 Phase 1
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Recruiting NCT05771428 - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT06114745 - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Phase 1